ACTolog in Patients With Solid Cancers

Fludarabine infusion

Cyclophosphamide infusion

i.v. infusion of IMA101 product(s).

Low dose IL-2 Infusion for two weeks

IMADetect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMADetect is intended for investigational use only.

Atezolizumab infusion will be given no earlier than 3 weeks post IMA101 infusion and after hematologic recovery is achieved, thereafter every 3 weeks until 1 year after IMA101 infusion.